Tuomas R. Holmberg
Fondateur chez NovaDigm Therapeutics, Inc.
Postes actifs de Tuomas R. Holmberg
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Directeur/Membre du Conseil | 01/01/2005 | - |
| Fondateur | 01/01/2005 | - | |
| Corporate Officer/Principal | 01/01/2005 | - |
Historique de carrière de Tuomas R. Holmberg
Anciens postes connus de Tuomas R. Holmberg
| Sociétés | Poste | Début | Fin |
|---|
Formation de Tuomas R. Holmberg
| University of Southern California | Masters Business Admin |
| California Institute of Technology | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
- Bourse
- Insiders
- Tuomas R. Holmberg
- Expérience
